Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine
NCT ID: NCT04361721
Last Updated: 2021-04-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
40 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-01-15
Study Completion Date
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Monoclonal antibodies (mABs) targeting calcitonin gene-related peptide (CGRP) proved effective in the preventive treatment of episodic and chronic migraine as well as in difficult-to-treat patients such as those who had previously failed multiple prevention treatments or those with associated medication overuse (MO).
A characteristic dysfunction in Chronic Migraine (CM) is sensitization, occurring peripherally in the trigeminovascular system but then spreading to the central nervous system, where it manifests with an increased neuronal excitability in multiple areas. Several neurophysiological studies in CM patients have demonstrated the occurrence of central sensitization in the brain as well as at the spinal level.
MicroRNAs (miRNAs) are involved in the generation and maintenance of chronic pain. Current evidence suggests that specific miRNAs may also play a role in migraine, thus representing possible biomarkers of the disease. A previous study reported an upregulation of miR-34a-5p and miR-382-5p, implicated in the regulation of GABAergic signaling and IL-10 gene expression respectively, during migraine attacks.
The aim of this open label, hypothesis generating study is the evaluation of the impact of erenumab treatment on neurophysiological, biomolecular and psychological aspects in a representative cohort of CM patients who had previously failed at least 2 preventive treatments.
A characteristic dysfunction in Chronic Migraine (CM) is sensitization, occurring peripherally in the trigeminovascular system but then spreading to the central nervous system, where it manifests with an increased neuronal excitability in multiple areas. Several neurophysiological studies in CM patients have demonstrated the occurrence of central sensitization in the brain as well as at the spinal level.
MicroRNAs (miRNAs) are involved in the generation and maintenance of chronic pain. Current evidence suggests that specific miRNAs may also play a role in migraine, thus representing possible biomarkers of the disease. A previous study reported an upregulation of miR-34a-5p and miR-382-5p, implicated in the regulation of GABAergic signaling and IL-10 gene expression respectively, during migraine attacks.
The aim of this open label, hypothesis generating study is the evaluation of the impact of erenumab treatment on neurophysiological, biomolecular and psychological aspects in a representative cohort of CM patients who had previously failed at least 2 preventive treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
NCT04084314
Migraine
Migraine Disorders
Migraine Headache
COMPLETED
PHASE4
Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
NCT04592952
Migraine
UNKNOWN
PHASE4
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
NCT02174861
Treatment for Prevention of Chronic Migraine
COMPLETED
PHASE2
Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy
NCT04152434
Refractory Chronic Migraine
COMPLETED
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
NCT03867201
Migraine
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study consisted of a first screening visit with a Neurologist of the Headache Science Centre of the IRCCS Mondino Foundation, during which a full neurological and general examination was performed, and the data collected on the routine headache diary used by all patients attending Mondino Foundation was checked to confirm inclusion/exclusion criteria.
If a patient fulfilled criteria, he/she was enrolled in a baseline observation period for a month. At the end of the baseline observation period (T0), if inclusion/exclusion criteria were still satisfied, patients completed the following procedures: recording of clinical and demographical features, vital signs evaluation, neurophysiological assessment and psycological interview based on DSM (The Diagnostic and Statical Manual of Mental Disorders), venous blood sampling, and compilation of a set of self-administered questionnaires about psychological state, health status and quality of life.
At T0, the patients were treated with the first dose of erenumab 70 mg subcutaneously.
After 28 days (4 full weeks), patients returned for the second visit (T1) to report clinical variables and adverse events. During T1, the second injection of erenumab 70 mg was administered, while a third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval (T2). The last visit of the study (T3) was then planned 56 days from T1, that was 28 days after the last dose of erenumab. At T3, the patients were tested with the same multi-disciplinary evaluation performed at T0: recording of clinical and demographical features, vital signs evaluation, neurophysiological assessment, venous blood sampling, and compilation of questionnaires concerning patients' psychological state, health status and quality of life.
Nociceptive withdrawal reflex measurements. The nociceptive withdrawal reflex (NWR) is considered an objective and solid neurophysiological technique for the study of spinal nociceptive transmission. The reflex was recorded in the lower limb according to a well validated procedure, in a quiet environment by an expert technician between 09:00 AM and 11:00 AM. Patients were in a comfortable position with their ankle flexed at 90° and knee flexed at 130°. The sural nerve was stimulated electrically behind the lateral malleolus with a pair of Ag/AgCl surface electrodes. The electrical stimulation was made of 5 consecutive squared pulses (1 ms, 200 Hz), randomly delivered every 60-120 seconds. The electromyographic sweep (Synergy, Medelec, United Kingdom) was recorded from the capitis brevis of the homolateral biceps femoris with a pair of Ag/AgCl surface electrodes. A staircase method was used for all the threshold evaluations, and the intensity was increased by 0.3 mA per step. The recording parameters were: analysis time 300 ms, sensitivity 20 mV, and filter bandpass 3 to 3000 Hz.
The investigators first evaluated the single stimulus reflex threshold of the NWR (RTh), defined as the lowest intensity (mA) able to induce 3 consecutive stable muscular responses of at least 20 mV and 10 ms. They also evaluated the average AUC (Area Under the Curve - mV x ms), the average latency (ms), and the subjective pain perception rated on a 0-10 points visual analogue scale (VAS-RTh).
Then the investigators evaluated the temporal summation threshold (TST), by means of a train of 5 electrical stimuli at a frequency of 2 Hz. TST was defined as the lowest intensity (mA) able to elicit 3 consecutive stable muscular responses of at least 20 mV and 10 ms in the fourth and fifth electromyographic sweeps. They also evaluated the subjective pain perception of the first (VAS-TST-1) and fifth (VAS-TST-5) stimulus of the TST on a 0-10 points visual analogue scale.
MicroRNAs expression. The microRNA expression was evaluated by real-time reverse transcription (RT) PCR in peripheral blood mononuclear cell (PBMCs).
PBMCs isolation: blood samples (10 ml) was collected within ethylenediamine tetra-acetic acid containing tube from participants. The blood samples were diluted in 1:1 ratio with phosphate buffer saline (PBS) (Sigma). Diluted blood samples were slowly loaded into Ficoll separating solution (10 ml) (Sigma) and centrifuged at 800 g for 30 min at room temperature. PBMCs accumulated as the middle white monolayer, were washed twice in sterile PBS at 300 g for 15 min. After washing, PBMCs were pelleted and stored at -80° C until use.
MicroRNAs gene expression: isolation of RNA from PBMCs was carried out using the Direct-zol RNA Mini prep plus (Zymo Research). RNA concentration was determined by absorbance at 230 and 280 nm using the NanoDrop Spectrophotometer (Nanodrop™ Thermo Fisher Scientific, Euroclone Milano). Synthesis of cDNA was performed by using MirXMirna First strand Synthesis (Takara-Diatech, Jesi-An Italy) and TB Green q-Rt PCR is used (Takara-Diatech, Jesi-An Italy) to determine expression levels of miRNA-34a-5p and miRNA-382-5p. The denaturation was performed at 95°C and the amplification was performed through two-step cycling (95-60°C) for 40 cycles with a Light Cycler 480 Instrument RT-PCR Detection System (Roche, Milan, Italy). Target gene expression levels was normalized with U6 (a type of small nuclear RNA), used as housekeeping gene. Gene expression levels were calculated according to 2-∆Ct = 2 - (Ct gene - Ct housekeeping gene) formula by using Ct values.
Disability and psychological evaluations.
The battery included evaluations for:
4\) Migraine-related disability and associated features:
* the Migraine Disability Assessment (MIDAS) test: 0-5 (grade I): minimal disability, 6-10 (grade II): mild disability, 11-20 (grade III): moderate disability, 21-40 (grade IVa): severe disability, 41 and higher (grade IVb): very severe disability;
* the Headache Impact Test-6 (HIT-6): 49 or less: no impact, 50-55: some impact, 56-59: substantial impact, 60-78 severe impact;
* Nociceptive Rating Scale for the assessment of average intensity of migraine pain: 0 no pain - 10 very severe;
* Allodynia Symptom Checklist (ASC-12): 0-3: mild cutaneous allodynia, 6-8: moderate cutaneous allodynia, 9 and higher: severe cutaneous allodynia.
5\) Quality of life:
* the Migraine-Specific Quality-of-Life Questionnaire (MSQ): 14-item assessment, with each item rated on a 6-point scale (ranging from "none of the time" to "all of the time"). Raw scores are then transformed to a 100-point scale, with higher scores indicating better quality of life;
* Short Form Health Survey (SF-36): 11-item assessment referring to two main sub-domains, namely the Mental Component Summary (MCS), and the Physical Component Summary (PCS);
* HEALTH 0-100: patients were asked to score on a scale range of 0-100 their general health status at the precise moment of evaluation.
6\) Psychological State:
* Hospital Anxiety and Depression Scale (HADS): a 14-items questionnaire on a 4-point (0-3) Likert scale assessing symptoms of anxiety and depression. A score of 8 or higher in the two different domains is considered significant for anxiety and/or depression;
* Leeds Dependence Questionnaire (LDQ): a 10-item instrument on 0-3 scale to measure dependence upon a variety of substances. No cut-off score indicative of dependence has been established;
* Toronto Alexithymia Scale (TAS-20): a 20-item questionnaire on a 5-point (1-5) Likert scale assessing alexithymia traits, i.e., individuals' difficulty in expressing their own feelings in words. A score of 61 or higher was considered significant for the presence of alexithymia;
* Childhood trauma questionnaire: including 13 items referring to different types of childhood traumas that were considered in term of total number of traumatic experiences;
* Stressful life-events questionnaire: consisting in a list of 58 stressful life events (e.g., moving, divorce, new work, dismissal, etc.). Patients were requested to tick those events that had occurred to them in the last 10 years.
If a patient fulfilled criteria, he/she was enrolled in a baseline observation period for a month. At the end of the baseline observation period (T0), if inclusion/exclusion criteria were still satisfied, patients completed the following procedures: recording of clinical and demographical features, vital signs evaluation, neurophysiological assessment and psycological interview based on DSM (The Diagnostic and Statical Manual of Mental Disorders), venous blood sampling, and compilation of a set of self-administered questionnaires about psychological state, health status and quality of life.
At T0, the patients were treated with the first dose of erenumab 70 mg subcutaneously.
After 28 days (4 full weeks), patients returned for the second visit (T1) to report clinical variables and adverse events. During T1, the second injection of erenumab 70 mg was administered, while a third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval (T2). The last visit of the study (T3) was then planned 56 days from T1, that was 28 days after the last dose of erenumab. At T3, the patients were tested with the same multi-disciplinary evaluation performed at T0: recording of clinical and demographical features, vital signs evaluation, neurophysiological assessment, venous blood sampling, and compilation of questionnaires concerning patients' psychological state, health status and quality of life.
Nociceptive withdrawal reflex measurements. The nociceptive withdrawal reflex (NWR) is considered an objective and solid neurophysiological technique for the study of spinal nociceptive transmission. The reflex was recorded in the lower limb according to a well validated procedure, in a quiet environment by an expert technician between 09:00 AM and 11:00 AM. Patients were in a comfortable position with their ankle flexed at 90° and knee flexed at 130°. The sural nerve was stimulated electrically behind the lateral malleolus with a pair of Ag/AgCl surface electrodes. The electrical stimulation was made of 5 consecutive squared pulses (1 ms, 200 Hz), randomly delivered every 60-120 seconds. The electromyographic sweep (Synergy, Medelec, United Kingdom) was recorded from the capitis brevis of the homolateral biceps femoris with a pair of Ag/AgCl surface electrodes. A staircase method was used for all the threshold evaluations, and the intensity was increased by 0.3 mA per step. The recording parameters were: analysis time 300 ms, sensitivity 20 mV, and filter bandpass 3 to 3000 Hz.
The investigators first evaluated the single stimulus reflex threshold of the NWR (RTh), defined as the lowest intensity (mA) able to induce 3 consecutive stable muscular responses of at least 20 mV and 10 ms. They also evaluated the average AUC (Area Under the Curve - mV x ms), the average latency (ms), and the subjective pain perception rated on a 0-10 points visual analogue scale (VAS-RTh).
Then the investigators evaluated the temporal summation threshold (TST), by means of a train of 5 electrical stimuli at a frequency of 2 Hz. TST was defined as the lowest intensity (mA) able to elicit 3 consecutive stable muscular responses of at least 20 mV and 10 ms in the fourth and fifth electromyographic sweeps. They also evaluated the subjective pain perception of the first (VAS-TST-1) and fifth (VAS-TST-5) stimulus of the TST on a 0-10 points visual analogue scale.
MicroRNAs expression. The microRNA expression was evaluated by real-time reverse transcription (RT) PCR in peripheral blood mononuclear cell (PBMCs).
PBMCs isolation: blood samples (10 ml) was collected within ethylenediamine tetra-acetic acid containing tube from participants. The blood samples were diluted in 1:1 ratio with phosphate buffer saline (PBS) (Sigma). Diluted blood samples were slowly loaded into Ficoll separating solution (10 ml) (Sigma) and centrifuged at 800 g for 30 min at room temperature. PBMCs accumulated as the middle white monolayer, were washed twice in sterile PBS at 300 g for 15 min. After washing, PBMCs were pelleted and stored at -80° C until use.
MicroRNAs gene expression: isolation of RNA from PBMCs was carried out using the Direct-zol RNA Mini prep plus (Zymo Research). RNA concentration was determined by absorbance at 230 and 280 nm using the NanoDrop Spectrophotometer (Nanodrop™ Thermo Fisher Scientific, Euroclone Milano). Synthesis of cDNA was performed by using MirXMirna First strand Synthesis (Takara-Diatech, Jesi-An Italy) and TB Green q-Rt PCR is used (Takara-Diatech, Jesi-An Italy) to determine expression levels of miRNA-34a-5p and miRNA-382-5p. The denaturation was performed at 95°C and the amplification was performed through two-step cycling (95-60°C) for 40 cycles with a Light Cycler 480 Instrument RT-PCR Detection System (Roche, Milan, Italy). Target gene expression levels was normalized with U6 (a type of small nuclear RNA), used as housekeeping gene. Gene expression levels were calculated according to 2-∆Ct = 2 - (Ct gene - Ct housekeeping gene) formula by using Ct values.
Disability and psychological evaluations.
The battery included evaluations for:
4\) Migraine-related disability and associated features:
* the Migraine Disability Assessment (MIDAS) test: 0-5 (grade I): minimal disability, 6-10 (grade II): mild disability, 11-20 (grade III): moderate disability, 21-40 (grade IVa): severe disability, 41 and higher (grade IVb): very severe disability;
* the Headache Impact Test-6 (HIT-6): 49 or less: no impact, 50-55: some impact, 56-59: substantial impact, 60-78 severe impact;
* Nociceptive Rating Scale for the assessment of average intensity of migraine pain: 0 no pain - 10 very severe;
* Allodynia Symptom Checklist (ASC-12): 0-3: mild cutaneous allodynia, 6-8: moderate cutaneous allodynia, 9 and higher: severe cutaneous allodynia.
5\) Quality of life:
* the Migraine-Specific Quality-of-Life Questionnaire (MSQ): 14-item assessment, with each item rated on a 6-point scale (ranging from "none of the time" to "all of the time"). Raw scores are then transformed to a 100-point scale, with higher scores indicating better quality of life;
* Short Form Health Survey (SF-36): 11-item assessment referring to two main sub-domains, namely the Mental Component Summary (MCS), and the Physical Component Summary (PCS);
* HEALTH 0-100: patients were asked to score on a scale range of 0-100 their general health status at the precise moment of evaluation.
6\) Psychological State:
* Hospital Anxiety and Depression Scale (HADS): a 14-items questionnaire on a 4-point (0-3) Likert scale assessing symptoms of anxiety and depression. A score of 8 or higher in the two different domains is considered significant for anxiety and/or depression;
* Leeds Dependence Questionnaire (LDQ): a 10-item instrument on 0-3 scale to measure dependence upon a variety of substances. No cut-off score indicative of dependence has been established;
* Toronto Alexithymia Scale (TAS-20): a 20-item questionnaire on a 5-point (1-5) Likert scale assessing alexithymia traits, i.e., individuals' difficulty in expressing their own feelings in words. A score of 61 or higher was considered significant for the presence of alexithymia;
* Childhood trauma questionnaire: including 13 items referring to different types of childhood traumas that were considered in term of total number of traumatic experiences;
* Stressful life-events questionnaire: consisting in a list of 58 stressful life events (e.g., moving, divorce, new work, dismissal, etc.). Patients were requested to tick those events that had occurred to them in the last 10 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Migraine
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic migraine patients
Three monthly administration of erenumab 70 mg subcutaneously.
Erenumab
Intervention Type
DRUG
First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erenumab
First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18 to 65 years
* history of CM or CM+MO for at least 12 months prior to enrollment \[10\]
* previous failure of at least two different pharmacological classes of preventive therapies
* history of CM or CM+MO for at least 12 months prior to enrollment \[10\]
* previous failure of at least two different pharmacological classes of preventive therapies
Exclusion Criteria
* other neurologic or neuropsychiatric diseases
* other chronic painful syndromes
* other types of primary or secondary headaches
* use of more than one preventive medication at baseline
* previous reported adverse reaction to latex
* pregnancy or lactation
* other chronic painful syndromes
* other types of primary or secondary headaches
* use of more than one preventive medication at baseline
* previous reported adverse reaction to latex
* pregnancy or lactation
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS National Neurological Institute "C. Mondino" Foundation
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cristina Tassorelli, MD
Role: PRINCIPAL_INVESTIGATOR
IRCCS Mondino Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Mondino Foundation
Pavia, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019 Nov 9;394(10210):1765-1774. doi: 10.1016/S0140-6736(19)32504-8. Epub 2019 Oct 23.
Reference Type
BACKGROUND
Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018 Sep;38(10):1611-1621. doi: 10.1177/0333102418788347. Epub 2018 Jul 8.
Reference Type
BACKGROUND
Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.
Reference Type
BACKGROUND
Coppola G, Di Lorenzo C, Schoenen J, Pierelli F. Habituation and sensitization in primary headaches. J Headache Pain. 2013 Jul 30;14(1):65. doi: 10.1186/1129-2377-14-65.
Reference Type
BACKGROUND
De Icco R, Perrotta A, Grillo V, Cosentino G, Sances G, Sandrini G, Tassorelli C. Experimentally induced spinal nociceptive sensitization increases with migraine frequency: a single-blind controlled study. Pain. 2020 Feb;161(2):429-438. doi: 10.1097/j.pain.0000000000001726.
Reference Type
BACKGROUND
Andersen HH, Duroux M, Gazerani P. Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain-Free Periods. Mol Neurobiol. 2016 Apr;53(3):1494-1500. doi: 10.1007/s12035-015-9106-5. Epub 2015 Feb 1.
Reference Type
BACKGROUND
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available.
Reference Type
BACKGROUND
Demartini C, Greco R, Zanaboni AM, Sances G, De Icco R, Borsook D, Tassorelli C. Nitroglycerin as a comparative experimental model of migraine pain: From animal to human and back. Prog Neurobiol. 2019 Jun;177:15-32. doi: 10.1016/j.pneurobio.2019.02.002. Epub 2019 Feb 13.
Reference Type
BACKGROUND
Sandrini G, Serrao M, Rossi P, Romaniello A, Cruccu G, Willer JC. The lower limb flexion reflex in humans. Prog Neurobiol. 2005 Dec;77(6):353-95. doi: 10.1016/j.pneurobio.2005.11.003. Epub 2005 Dec 28.
Reference Type
BACKGROUND
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8. doi: 10.1038/nprot.2008.73.
Reference Type
BACKGROUND
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20-8. doi: 10.1212/wnl.56.suppl_1.s20.
Reference Type
BACKGROUND
Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003 Dec;12(8):963-74. doi: 10.1023/a:1026119331193.
Reference Type
BACKGROUND
Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF; American Migraine Prevalence Prevention Advisory Group. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 Feb;63(2):148-58. doi: 10.1002/ana.21211.
Reference Type
BACKGROUND
Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998 Apr;38(4):295-302. doi: 10.1046/j.1526-4610.1998.3804295.x.
Reference Type
BACKGROUND
Apolone G, Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol. 1998 Nov;51(11):1025-36. doi: 10.1016/s0895-4356(98)00094-8.
Reference Type
BACKGROUND
Scalone L, Cortesi PA, Mantovani LG, Ciampichini R, Cesana G. Reference Eq-5d-3l and Eq-5d-5l Data From the Italian General Population. Value Health. 2014 Nov;17(7):A514-5. doi: 10.1016/j.jval.2014.08.1591. Epub 2014 Oct 26. No abstract available.
Reference Type
BACKGROUND
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. doi: 10.1016/s0022-3999(01)00296-3.
Reference Type
BACKGROUND
Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994 May;89(5):563-72. doi: 10.1111/j.1360-0443.1994.tb03332.x.
Reference Type
BACKGROUND
Bagby RM, Parker JDA, Taylor GJ. Twenty-five years with the 20-item Toronto Alexithymia Scale. J Psychosom Res. 2020 Apr;131:109940. doi: 10.1016/j.jpsychores.2020.109940. Epub 2020 Jan 23.
Reference Type
BACKGROUND
Bottiroli S, Galli F, Viana M, Sances G, Tassorelli C. Traumatic Experiences, Stressful Events, and Alexithymia in Chronic Migraine With Medication Overuse. Front Psychol. 2018 May 14;9:704. doi: 10.3389/fpsyg.2018.00704. eCollection 2018.
Reference Type
BACKGROUND
Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G. Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain. 2021 Oct 2;22(1):114. doi: 10.1186/s10194-021-01333-4.
Reference Type
DERIVED
De Icco R, Fiamingo G, Greco R, Bottiroli S, Demartini C, Zanaboni AM, Allena M, Guaschino E, Martinelli D, Putorti A, Grillo V, Sances G, Tassorelli C. Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study. Cephalalgia. 2020 Oct;40(12):1336-1345. doi: 10.1177/0333102420942230. Epub 2020 Jul 26.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EreCM2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
NCT04271202
COMPLETED
PHASE4
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
NCT04452929
UNKNOWN
NA
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT03977649
COMPLETED
PHASE4
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment
NCT03481400
UNKNOWN
NA
Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment
NCT05442008
COMPLETED
A Controlled Trial of Erenumab in Migraine Prevention
NCT03812224
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
NCT02066415
COMPLETED
PHASE2
Psychological and Biological Markers of Refractory Migraine
NCT05046119
UNKNOWN
Efficacy of OnabotulinumtoxinA in Migraine
NCT04578782
COMPLETED
PHASE2
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
NCT05281770
RECRUITING
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
NCT04825678
COMPLETED
PHASE4
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
NCT04252742
COMPLETED
PHASE4
Efficacy of Erenumab in Chronic Cluster Headache
NCT04970355
COMPLETED
PHASE2
MicroRNA Profile and Erenumab Treatment
NCT04659226
COMPLETED
NA
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
NCT04921384
COMPLETED
PHASE3
Effectiveness and Tolerability of Eptinezumab
NCT06409845
RECRUITING
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
NCT03828539
COMPLETED
PHASE4
Neuro-Complex & Multi Supplements for Migraine Prevention
NCT07015411
RECRUITING
NA
The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy
NCT07040813
RECRUITING
PHASE3
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750
RECRUITING
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188
RECRUITING
NA
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
NCT04418765
COMPLETED
PHASE3
Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.
NCT05635604
COMPLETED
NA
Registry for Migraine - Clinical Core
NCT04603976
UNKNOWN
PHASE4
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
NCT06701526
RECRUITING
PHASE4